# A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma

> **NCT02385669** · PHASE1,PHASE2 · TERMINATED · sponsor: **Craig L Slingluff, Jr** · enrollment: 3 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **BIOLOGICAL:** 6MHP

## Key facts

- **NCT ID:** NCT02385669
- **Lead sponsor:** Craig L Slingluff, Jr
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2019-09-18
- **Final completion:** 2019-09-18
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** why study stopped
- **Last updated:** 2020-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02385669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02385669, "A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02385669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*